Page 67 - Read Online

Page 14 of 18 Malone et al. J Cancer Metastasis Treat 2021;7:40 https://dx.doi.org/10.20517/2394-4722.2021.37

PubMed PMC
15. Massagué J, Ganesh K. Metastasis-initiating cells and ecosystems. Cancer Discov 2021;11:971-994. DOI PubMed PMC
16. Pereira ER, Kedrin D, Seano G, et al. Lymph node metastases can invade local blood vessels, exit the node, and colonize distant
organs in mice. Science 2018;359:1403-7. DOI PubMed PMC
17. Heitz F, Harter P, Lueck HJ, et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier
occurrence of cerebral metastases. Eur J Cancer 2009;45:2792-8. DOI PubMed
18. Heitz F, Rochon J, Harter P, et al. Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival. Ann
Oncol 2011;22:1571-81. DOI PubMed
19. Miller KD, Weathers T, Haney LG, et al. Occult central nervous system involvement in patients with metastatic breast cancer:
prevalence, predictive factors and impact on overall survival. Ann Oncol 2003;14:1072-7. DOI PubMed
20. Niikura N, Hayashi N, Masuda N, et al. Treatment outcomes and prognostic factors for patients with brain metastases from breast
cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat 2014;147:103-12. DOI PubMed
21. Pestalozzi BC, Zahrieh D, Price KN, et al; International Breast Cancer Study Group (IBCSG). Identifying breast cancer patients at
risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol
2006;17:935-44. DOI PubMed
22. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol
2005;167:913-20. DOI PubMed PMC
23. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-7. DOI
PubMed
24. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008;68:3108-14. DOI
PubMed
25. Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett 2017;387:61-8. DOI PubMed
26. Arciero CA, Guo Y, Jiang R, et al. ER(+)/HER2(+) breast cancer has different metastatic patterns and better survival than ER(-
)/HER2(+) breast cancer. Clin Breast Cancer 2019;19:236-45. DOI PubMed
27. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer
1989;63:181-7. DOI PubMed
28. Koscielny S, Tubiana M, Lê MG, et al. Breast cancer: relationship between the size of the primary tumour and the probability of
metastatic dissemination. Br J Cancer 1984;49:709-15. DOI PubMed PMC
29. Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.
Oncologist 2003;8:307-25. DOI PubMed
30. Hellman S. Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol 1994;12:2229-34. DOI PubMed
31. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0)
breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989;7:1239-51. DOI PubMed
32. Page DL. Prognosis and breast cancer. Recognition of lethal and favorable prognostic types. Am J Surg Pathol 1991;15:334-49. DOI
PubMed
33. Laura S, Coombs NJ, Ung O, Boyages J. Tumour size as a predictor of axillary node metastases in patients with breast cancer. ANZ J
Surg 2006;76:1002-6. DOI PubMed
34. Sivaramakrishna R, Gordon R. Detection of breast cancer at a smaller size can reduce the likelihood of metastatic spread: a
quantitative analysis. Acad Radiol 1997;4:8-12. DOI PubMed
35. Caswell DR, Swanton C. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical
outcome. BMC Med 2017;15:133. DOI PubMed PMC
36. Foulds L. The natural history of cancer. J Chronic Dis 1958;8:2-37. DOI PubMed
37. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8. DOI
PubMed
38. Pontén J. Natural history of breast cancer. Acta Oncol 1990;29:325-9. DOI PubMed
39. Sopik V, Narod SA. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast
Cancer Res Treat 2018;170:647-56. DOI PubMed PMC
40. Narod SA, Sopik V. Is invasion a necessary step for metastases in breast cancer? Breast Cancer Res 2018;169:9-23. DOI PubMed
PMC
41. Schlicker A, Ellappalayam A, Beumer IJ, et al. Investigating the concordance in molecular subtypes of primary colorectal tumors and
their matched synchronous liver metastasis. Int J Cancer 2020;147:2303-15. DOI PubMed
42. Priedigkeit N, Hartmaier RJ, Chen Y, et al. Intrinsic subtype switching and acquired ERBB2/HER2 amplifications and mutations in
breast cancer brain metastases. JAMA Oncol 2017;3:666-71. DOI PubMed PMC
43. Brastianos PK, Carter SL, Santagata S, et al. Genomic characterization of brain metastases reveals branched evolution and potential
therapeutic targets. Cancer Discov 2015;5:1164-77. DOI PubMed PMC
44. Wei S, Siegal GP. Surviving at a distant site: The organotropism of metastatic breast cancer. Semin Diagn Pathol 2018;35:108-11.
DOI PubMed
45. Oehrlich NE, Spineli LM, Papendorf F, Park-Simon TW. Clinical outcome of brain metastases differs significantly among breast
cancer subtypes. Oncol Lett 2017;14:194-200. DOI PubMed PMC
46. Kim YJ, Kim JS, Kim IA. Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER
database. J Cancer Res Clin Oncol 2018;144:1803-16. DOI PubMed